SCHEMBL218890

SCHEMBL218890

Cc1ccc(-c2cn3cc(-c4csc(CO)c4)ccc3n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 9/20 0.56
SLC2A1 P11166 1/20 0.56
NPC1 O15118 8/20 0.55
RAB9A P51151 7/20 0.55
ALDH1A1 P00352 6/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
KDM4E B2RXH2 4/20 0.55
PAX8 Q06710 2/20 0.55
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
MITF O75030 1/20 0.55
KDM5A P29375 1/20 0.55
KDM5C P41229 1/20 0.55
CYP2C9 P11712 1/20 0.48
NR4A2 P43354 1/20 0.48
KCNH2 Q12809 1/20 0.48
APP P05067 2/20 0.47
TP53 P04637 2/20 0.47
ALDH1A2 O94788 1/20 0.47
PKM P14618 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL219585 0.90 ALDH1A3 (0.61) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL216921 0.89 ALDH1A3 (0.56) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL218476 0.89 NR4A2 (0.62) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL220441 0.88 ALDH1A3 (0.59) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL220443 0.87 NR4A2 (0.41) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL219931 0.86 ALDH1A1 (0.56) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL219611 0.86 CYP2C9 (0.46) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL220036 0.85 NR4A2 (0.44) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL219023 0.84 ALDH1A1 (0.45) ALDH1A3SLC2A1NPC1RAB9AALDH1A1
SCHEMBL220168 0.84 NR4A2 (0.47) ALDH1A3SLC2A1NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262804-B1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-12-03 EP claimed
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US claimed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US claimed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US disclosed
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-03-01 US disclosed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US disclosed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262804-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2010-12-22 EP disclosed
WO-2009144392-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 ALDH1A3 2936/4885SLC2A1 2990/4885NPC1 1704/4885
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 ALDH1A3 2936/4885SLC2A1 2990/4885NPC1 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.